Christian Jackisch

Frankfurt Am Main, HE, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 284 publications

Plain language summary about how patients with HER2 positive breast cancer across Europe feel about their cancer, treatment, and future health and related implications for their treatment journey.

Plain language summary about how patients with HER2 positive breast cancer across Europe feel about their cancer, treatment, and future health and related implications for their treatment journey.

Journal: Future oncology (London, England)

Published: May 13, 2026

Final analysis of the FeDeriCa phase III study: long-term efficacy, safety and pharmacokinetics of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection, plus chemotherapy, in HER2-positive early breast cancer.

Final analysis of the FeDeriCa phase III study: long-term efficacy, safety and pharmacokinetics of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection, plus chemotherapy, in HER2-positive early breast cancer.

Journal: ESMO open

Published: November 10, 2025

National policies for screening and early detection of breast cancer around the globe: Practices, barriers, and solutions.

National policies for screening and early detection of breast cancer around the globe: Practices, barriers, and solutions.

Journal: International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics

Published: June 30, 2025

Patient preferences for treatment pathways in early-stage breast cancer: application of a discrete choice experiment.

Patient preferences for treatment pathways in early-stage breast cancer: application of a discrete choice experiment.

Journal: Future oncology (London, England)

Published: June 16, 2025

Treatment Experience of Early-Stage Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer in a Real-World Setting: European Patients' Perspectives.

Treatment Experience of Early-Stage Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer in a Real-World Setting: European Patients' Perspectives.

Journal: Breast care (Basel, Switzerland)

Published: June 10, 2025

Real-world progression-free survival and overall survival in patients with HR+/HER2- advanced breast cancer treated in first-line with ribociclib, endocrine monotherapy or chemotherapy: Results from the observational RIBANNA study.

Real-world progression-free survival and overall survival in patients with HR+/HER2- advanced breast cancer treated in first-line with ribociclib, endocrine monotherapy or chemotherapy: Results from the observational RIBANNA study.

Journal: International journal of cancer

Published: April 07, 2025

Long-term outcome data for patients with hormone receptor-positive early breast cancer participating in the WSG PlanB trial after preselection by gene expression analysis: 10-year survival results from the WSG PlanB registry.

Long-term outcome data for patients with hormone receptor-positive early breast cancer participating in the WSG PlanB trial after preselection by gene expression analysis: 10-year survival results from the WSG PlanB registry.

Journal: ESMO open

Published: March 28, 2025

Conditional progression-free survival in patients with metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with first-line ribociclib and endocrine therapy: real-world data from the RIBANNA study.

Conditional progression-free survival in patients with metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with first-line ribociclib and endocrine therapy: real-world data from the RIBANNA study.

Journal: ESMO open

Published: February 03, 2025

Safety with the senhance™ robotic system in 3,239 patients across various surgical disciplines.

Safety with the senhance™ robotic system in 3,239 patients across various surgical disciplines.

Journal: Langenbeck's archives of surgery

Published: January 18, 2025

Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer.

Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer.

Journal: The New England journal of medicine

Published: January 15, 2025

Eribulin-Induced Peripheral Neuropathy in Locally Advanced or Metastatic Breast Cancer: Final Analysis of the Prospective Cohort IRENE Study.

Eribulin-Induced Peripheral Neuropathy in Locally Advanced or Metastatic Breast Cancer: Final Analysis of the Prospective Cohort IRENE Study.

Journal: Cancers

Published: November 26, 2024

Update Breast Cancer 2024 Part 3 - Patients with Advanced Stage Breast Cancer.

Update Breast Cancer 2024 Part 3 - Patients with Advanced Stage Breast Cancer.

Journal: Geburtshilfe und Frauenheilkunde

Published: November 20, 2024

Showing 1-12 of 284

Last Updated: 09/26/2026